While ImmunityBio Inc has overperformed by 0.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IBRX fell by -18.12%, with highs and lows ranging from $10.53 to $2.28, whereas the simple moving average fell by -29.57% in the last 200 days.
On January 10, 2025, BTIG Research started tracking ImmunityBio Inc (NASDAQ: IBRX) recommending Buy. A report published by Piper Sandler on May 12, 2023, Downgraded its rating to ‘Neutral’ for IBRX. Jefferies also rated IBRX shares as ‘Buy’, setting a target price of $8 on the company’s shares in an initiating report dated August 03, 2022.
Analysis of ImmunityBio Inc (IBRX)
Further, the quarter-over-quarter increase in sales is 7346.34%, showing a positive trend in the upcoming months.
In order to gain a clear picture of ImmunityBio Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. Taking into account the quick ratio of the company, currently set at 2.64, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 5.93M can be a very valuable indicator of volatility for IBRX stock. On a monthly basis, the volatility of the stock is set at 10.06%, whereas on a weekly basis, it is put at 6.00%, with a gain of 5.94% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.19, showing growth from the present price of $3.39, which can serve as yet another indication of whether IBRX is worth investing in or should be passed over.
How Do You Analyze ImmunityBio Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 89.63%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 9.68% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IBRX shares are owned by institutional investors to the tune of 9.68% at present.
